Gavrilovic Igor T, Abrey Lauren E
Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
Curr Oncol Rep. 2005 Jan;7(1):47-54. doi: 10.1007/s11912-005-0025-x.
Primary central nervous system lymphoma (PCNSL) is an uncommon form of non-Hodgkin's lymphoma (NHL) that has been increasing in incidence over the past three decades. Unlike systemic extranodal NHL, the response to therapy for PCNSL patients has been somewhat unsatisfactory. However, methotrexate-based chemotherapy and whole-brain radiotherapy have improved the outcome of patients. Unfortunately, treatment-related neurotoxicity is common, especially in the elderly. Although progress has been made in treating PCNSL, there remains no optimal methotrexate dose or frequency. Treatment of recurrence also remains controversial. These important questions have prompted several clinical studies looking at novel ways to intensify chemotherapy and limit neurotoxicity.
原发性中枢神经系统淋巴瘤（PCNSL）是一种罕见的非霍奇金淋巴瘤（NHL）形式，在过去三十年中发病率一直在上升。与系统性结外NHL不同，PCNSL患者的治疗反应一直不太令人满意。然而，基于甲氨蝶呤的化疗和全脑放疗改善了患者的预后。不幸的是，治疗相关的神经毒性很常见，尤其是在老年人中。尽管在治疗PCNSL方面取得了进展，但仍然没有最佳的甲氨蝶呤剂量或频率。复发的治疗也仍然存在争议。这些重要问题促使了几项临床研究探索强化化疗和限制神经毒性的新方法。
